Advanced Endometrial Cancer Clinical Trial
Official title:
A Phase 2, Open-Label, Safety Lead-In With Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab
This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients. A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04574284 -
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
|
Phase 2 | |
| Withdrawn |
NCT06046274 -
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT05112991 -
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT01289041 -
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05077215 -
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
|
Phase 3 | |
| Recruiting |
NCT05481645 -
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
|
Phase 2 |